AAAAAA

   
Results: 1-8 |
Results: 8
Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms
Authors: Bantar, C Nicola, F Canigia, LF Arenoso, HJ Soutric, J Montoto, M Blanco, M Smayevsky, J Jasovich, A
Citation: C. Bantar et al., Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms, J CHEMOTHER, 13(4), 2001, pp. 402-406
Alarming baseline rates of nosocomial infection and surgical prophylaxis errors in a small teaching hospital in Argentina
Authors: Bustos, JL Vesco, E Tosello, C Almara, A Boleas, M Magnin, E Salamone, F Sartori, B Morera, G Bantar, C
Citation: Jl. Bustos et al., Alarming baseline rates of nosocomial infection and surgical prophylaxis errors in a small teaching hospital in Argentina, INFECT CONT, 22(5), 2001, pp. 264-265
A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections
Authors: Bantar, C Nicola, F Canigia, LF Arenoso, HJ Soutric, J Montoto, M Blanco, M Smayevsky, J Jasovich, A
Citation: C. Bantar et al., A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections, J CHEMOTHER, 12(3), 2000, pp. 223-227
Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection
Authors: Smayevsky, J Lopez, H Di Chiara, M Scarano, S Lanza, A Vilches, V Stepanik, D Bantar, C Sucari, A
Citation: J. Smayevsky et al., Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection, DIAG MICR I, 37(4), 2000, pp. 261-264
Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains
Authors: Bantar, C Di Chiara, M Nicola, F Relloso, S Smayevsky, J
Citation: C. Bantar et al., Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains, DIAG MICR I, 37(1), 2000, pp. 41-44
Comparison of several methods to determine methicillin-resistance in Staphylococcus aureus with focus on borderline strains
Authors: Nicola, F Bantar, C Canigia, LF Relloso, S Bianchini, H Smayevsky, J
Citation: F. Nicola et al., Comparison of several methods to determine methicillin-resistance in Staphylococcus aureus with focus on borderline strains, DIAG MICR I, 36(2), 2000, pp. 91-93
Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections
Authors: Bantar, C Durlach, R Nicola, F Freuler, C Bonvehi, P Vazquez, R Smayevsky, J
Citation: C. Bantar et al., Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections, J ANTIMICRO, 43(5), 1999, pp. 737-740
Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli
Authors: Bantar, C Nicola, F Arenoso, HJ Galas, M Soria, L Dana, D Rossi, A Bianchini, H Jasovich, A
Citation: C. Bantar et al., Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli, ANTIM AG CH, 43(6), 1999, pp. 1503-1504
Risultati: 1-8 |